A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered
in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU
and leucovorin.
Phase:
Phase 1
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc